Cornerstone Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cornerstone Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Buy	+24,760	New	+$11M	0.41%	71
2026 Q1	–	Sell	-10,700	Closed	-$4.85M	–	165
2025 Q4	$4.85M	Sell	10,700 -25,400	-70%	-$10.9M	0.16%	125
2025 Q3	$14.1M	Sell	36,100 -500	-1%	-$209K	0.47%	54
2025 Q2	$16.3M	Buy	36,600 +23,600	+182%	+$10.9M	0.56%	47
2025 Q1	$6.3M	Hold	13,000	–	–	0.27%	93
2024 Q4	$5.24M	Hold	13,000	–	–	0.21%	108
2024 Q3	$6.05M	Buy	13,000 +800	+7%	+$384K	0.24%	103
2024 Q2	$5.72M	Sell	12,200 -100	-0.8%	-$43.4K	0.23%	107
2024 Q1	$5.14M	Hold	12,300	–	–	0.21%	119
2023 Q4	$5M	Sell	12,300 -4,800	-28%	-$1.77M	0.22%	117
2023 Q3	$5.95M	Sell	17,100 -6,200	-27%	-$2.17M	0.28%	102
2023 Q2	$8.2M	Buy	23,300 +3,300	+17%	+$1.11M	0.39%	71
2023 Q1	$6.3M	Hold	20,000	–	–	0.29%	82
2022 Q4	$5.78M	Sell	20,000 -7,000	-26%	-$2.13M	0.29%	93
2022 Q3	$7.82M	Hold	27,000	–	–	0.38%	73
2022 Q2	$7.61M	Buy	27,000 +5,000	+23%	+$1.34M	0.4%	70
2022 Q1	$5.74M	Hold	22,000	–	–	0.34%	77
2021 Q4	$4.83M	Hold	22,000	–	–	0.26%	95
2021 Q3	$3.99M	Hold	22,000	–	–	0.23%	112
2021 Q2	$4.44M	Buy	22,000 +9,000	+69%	+$1.88M	0.26%	104
2021 Q1	$2.79M	Sell	13,000 -7,000	-35%	-$1.54M	0.24%	102
2020 Q4	$4.73M	Hold	20,000	–	–	0.41%	58
2020 Q3	$5.44M	Hold	20,000	–	–	0.49%	50
2020 Q2	$5.81M	Buy	20,000 +7,000	+54%	+$1.9M	0.54%	44
2020 Q1	$3.09M	Buy	+13,000	New	+$2.98M	0.34%	72
2018 Q4	–	Sell	-9,000	Closed	-$1.74M	–	253
2018 Q3	$1.74M	Hold	9,000	–	–	0.13%	168
2018 Q2	$1.53M	Hold	9,000	–	–	0.19%	129
2018 Q1	$1.47M	Sell	9,000 -5,000	-36%	-$817K	0.17%	144
2017 Q4	$2.1M	Hold	14,000	–	–	0.24%	117
2017 Q3	$2.13M	Buy	14,000 +9,000	+180%	+$1.35M	0.25%	118
2017 Q2	$644K	Buy	+5,000	New	+$602K	0.12%	175

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cornerstone Advisors's VRTX Position: Q2 2026 in Review

Cornerstone Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 24,760 shares worth $12.3M. The stake represents 0.41% of the portfolio and ranks #71 among its holdings. This is a return to the name: Cornerstone Advisors previously reported a position in VRTX as recently as Q4 2025.

Cornerstone Advisors first reported a position in VRTX in Q2 2017 and has held it in 31 quarters since. The position peaked at $16.3M in Q2 2025. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Cornerstone Advisors held 24,760 shares of Vertex Pharmaceuticals worth $12.3M as of Q2 2026.
Vertex Pharmaceuticals was a new Cornerstone Advisors position in Q2 2026.
Vertex Pharmaceuticals made up 0.41% of Cornerstone Advisors's portfolio in Q2 2026, its #71 holding.
Cornerstone Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 31 quarters since.
Cornerstone Advisors's Vertex Pharmaceuticals position peaked at $16.3M in Q2 2025.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cornerstone Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.